Oncolytics Biotech Stock Analysis
| ONCY Stock | USD 0.93 0.02 2.11% |
Oncolytics Biotech is undervalued with Real Value of 2.51 and Target Price of 7.33. The main objective of Oncolytics Biotech stock analysis is to determine its intrinsic value, which is an estimate of what Oncolytics Biotech is worth, separate from its market price. There are two main types of Oncolytics Biotech's stock analysis: fundamental analysis and technical analysis.
The Oncolytics Biotech stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Oncolytics Biotech is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Oncolytics Stock trading window is adjusted to America/New York timezone.
Oncolytics |
Oncolytics Stock Analysis Notes
The company recorded a loss per share of 0.26. Oncolytics Biotech last dividend was issued on the 25th of May 2018. The entity had 10:95 split on the 25th of May 2018. Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada. Oncolytics Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people. To find out more about Oncolytics Biotech contact Dr MBA at 403 670 7377 or learn more at https://www.oncolyticsbiotech.com.Oncolytics Biotech Investment Alerts
| Oncolytics Biotech had very high historical volatility over the last 90 days | |
| Oncolytics Biotech has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (27.75 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Oncolytics Biotech currently holds about 32.36 M in cash with (28.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.55. | |
| Oncolytics Biotech has a poor financial position based on the latest SEC disclosures | |
| Latest headline from insidermonkey.com: Oncolytics Biotech Inc. Q3 2024 Earnings Call Transcript |
Oncolytics Biotech Upcoming and Recent Events
Earnings reports are used by Oncolytics Biotech to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 1st of March 2024 Upcoming Quarterly Report | View | |
| 3rd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 1st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Oncolytics Largest EPS Surprises
Earnings surprises can significantly impact Oncolytics Biotech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-09 | 2024-03-31 | -0.11 | -0.09 | 0.02 | 18 | ||
2022-08-11 | 2022-06-30 | -0.11 | -0.09 | 0.02 | 18 | ||
2020-11-11 | 2020-09-30 | -0.14 | -0.16 | -0.02 | 14 |
Oncolytics Stock Institutional Investors
| Shares | Bmo Capital Markets Corp. | 2024-06-30 | 37.4 K | Virtu Financial Llc | 2024-06-30 | 27.4 K | Brave Asset Management Inc | 2024-09-30 | 25 K | Newman Dignan & Sheerar Inc | 2024-09-30 | 22 K | Financial Advisory Corp /ut/ /adv | 2024-09-30 | 20.6 K | Lpl Financial Corp | 2024-09-30 | 20.5 K | Head & Associates, Llc | 2024-09-30 | 17.4 K | C2p Capital Advisory Group Llc Dba Prosperity Capital Advisors | 2024-09-30 | 15 K | Ausdal Financial Partners Inc | 2024-09-30 | 14 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 277 K | Seeds Investor Llc | 2024-09-30 | 189.9 K |
Oncolytics Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 75.82 M.Oncolytics Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.71) | (0.75) | |
| Return On Capital Employed | (0.98) | (1.03) | |
| Return On Assets | (0.71) | (0.75) | |
| Return On Equity | (1.01) | (0.96) |
Management Efficiency
Oncolytics Biotech has return on total asset (ROA) of (0.7133) % which means that it has lost $0.7133 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3822) %, meaning that it created substantial loss on money invested by shareholders. Oncolytics Biotech's management efficiency ratios could be used to measure how well Oncolytics Biotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.75 in 2024. Return On Capital Employed is likely to drop to -1.03 in 2024. At this time, Oncolytics Biotech's Other Current Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 32 M in 2024, whereas Total Assets are likely to drop slightly above 30.5 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.41 | 0.39 | |
| Tangible Book Value Per Share | 0.41 | 0.39 | |
| Enterprise Value Over EBITDA | (2.48) | (2.61) | |
| Price Book Value Ratio | 4.29 | 4.50 | |
| Enterprise Value Multiple | (2.48) | (2.61) | |
| Price Fair Value | 4.29 | 4.50 | |
| Enterprise Value | 83.7 M | 118 M |
Oncolytics Biotech showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Beta 1.506 | Return On Assets (0.71) | Return On Equity (1.38) |
Technical Drivers
As of the 1st of December, Oncolytics Biotech holds the Coefficient Of Variation of 6168.76, risk adjusted performance of 0.021, and Semi Deviation of 3.53. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Oncolytics Biotech, as well as the relationship between them.Oncolytics Biotech Price Movement Analysis
The output start index for this execution was nine with a total number of output elements of fifty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Oncolytics Biotech middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Oncolytics Biotech. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Oncolytics Biotech Outstanding Bonds
Oncolytics Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Oncolytics Biotech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Oncolytics bonds can be classified according to their maturity, which is the date when Oncolytics Biotech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Oncolytics Biotech Predictive Daily Indicators
Oncolytics Biotech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Oncolytics Biotech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Oncolytics Biotech Forecast Models
Oncolytics Biotech's time-series forecasting models are one of many Oncolytics Biotech's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Oncolytics Biotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Oncolytics Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Oncolytics Biotech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Oncolytics shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Oncolytics Biotech. By using and applying Oncolytics Stock analysis, traders can create a robust methodology for identifying Oncolytics entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (6.74) | (7.08) | |
| Operating Profit Margin | (6.81) | (7.15) | |
| Net Loss | (6.75) | (7.08) |
Current Oncolytics Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Oncolytics analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Oncolytics analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 7.33 | Strong Buy | 8 | Odds |
Most Oncolytics analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Oncolytics stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Oncolytics Biotech, talking to its executives and customers, or listening to Oncolytics conference calls.
Oncolytics Stock Analysis Indicators
Oncolytics Biotech stock analysis indicators help investors evaluate how Oncolytics Biotech stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Oncolytics Biotech shares will generate the highest return on investment. By understating and applying Oncolytics Biotech stock analysis, traders can identify Oncolytics Biotech position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 11.7 M | |
| Common Stock Shares Outstanding | 67.6 M | |
| Total Stockholder Equity | 27.6 M | |
| Tax Provision | 111 K | |
| Property Plant And Equipment Net | 647 K | |
| Cash And Short Term Investments | 34.9 M | |
| Cash | 34.9 M | |
| Accounts Payable | 1.1 M | |
| Net Debt | -34.5 M | |
| 50 Day M A | 1.0892 | |
| Total Current Liabilities | 4.2 M | |
| Other Operating Expenses | 33.8 M | |
| Non Current Assets Total | 647 K | |
| Non Currrent Assets Other | -1.00 | |
| Stock Based Compensation | 2.1 M |
Additional Tools for Oncolytics Stock Analysis
When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.